Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
grade B 8.11 1.37% 0.11
NERV closed up 1.37 percent on Monday, September 16, 2019, on 79 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical NERV trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 1.37%
Upper Bollinger Band Walk Strength 1.37%
Overbought Stochastic Strength 1.37%
Upper Bollinger Band Touch Strength 1.37%
Upper Bollinger Band Walk Strength 0.50%
Overbought Stochastic Strength 0.50%

Older signals for NERV ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Drugs Parkinson's Disease Schizophrenia Psychoactive Drugs Treatment Of Parkinson's Disease Major Depressive Disorder Neurochemistry Ketones Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases
Is NERV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.95
52 Week Low 4.07
Average Volume 272,448
200-Day Moving Average 6.9213
50-Day Moving Average 6.8906
20-Day Moving Average 7.2965
10-Day Moving Average 7.683
Average True Range 0.3846
ADX 33.66
+DI 30.7427
-DI 11.8345
Chandelier Exit (Long, 3 ATRs ) 7.4262
Chandelier Exit (Short, 3 ATRs ) 7.4938
Upper Bollinger Band 8.3441
Lower Bollinger Band 6.2489
Percent B (%b) 0.89
BandWidth 28.715137
MACD Line 0.3706
MACD Signal Line 0.2764
MACD Histogram 0.0942
Fundamentals Value
Market Cap 344.75 Million
Num Shares 42.5 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -7.51
Price-to-Sales 0.00
Price-to-Book 2.36
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.49
Resistance 3 (R3) 8.46 8.31 8.42
Resistance 2 (R2) 8.31 8.21 8.32 8.40
Resistance 1 (R1) 8.21 8.16 8.26 8.24 8.38
Pivot Point 8.06 8.06 8.09 8.07 8.06
Support 1 (S1) 7.96 7.96 8.01 7.99 7.84
Support 2 (S2) 7.81 7.91 7.82 7.82
Support 3 (S3) 7.71 7.81 7.80
Support 4 (S4) 7.74